References
- Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. National Heart, Lung, and Blood Institute, National Institutes of Health, National Heart, Lung, and Blood Institute. Available at:http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm [Last accessed 23 May 2008]
- Global Initiative for Asthma. Global strategy for asthma management and prevention 2006. Available at http://www.ginasthma.org [Last accessed 23 May 2008]
- Kelly HW. Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines. J Allergy Clin Immunol 2007;120:989-94
- Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730-4
- Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than the addition montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001;120:423-30
- Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination proves more effective asthma control than low-dose inhaled corticosteroids plus montelukast. J Allergy Clin Immunol 2000;106:1088-95
- Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999;103:1075-80
- Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids. Allen & Hanburys Limited UK Study Group. Lancet 1994;23:219-24
- Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8
- van Noord JA, Schreurs AJ, Mol SJ, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999;54:207-12
- O’Connor RD, O’Donnell JC, Pinto LA, et al. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest 2002;121:1028-35
- Stempel D, O’Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002;109(3):433-9
- Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245-51
- Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Compliance to asthma controller medication regimens. Resp Med 2005;99:1263-7
- Delea TE, Hagiwara M, Stanford R, Stempel DA. Utilization and costs of asthma-related care in patients initiating fluticasone propionate/salmeterol combination, salmeterol, or montelukast as add-on therapy to inhaled corticosteroids. Clin Ther 2008;30:560-71
- Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6
- Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids for the long term prevention of hospitalization for asthma. Thorax 2002;57:880-4
- Schatz M, Cook EF, Nakahiro R, et al. Inhaled corticosteroids and allergy speciality care reduce emergency hospital use for asthma. J Allergy Clin Immunol 2003;111:503-8
- Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114:1288-93
- Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
- McCullagh P, Nelder JA. Generalized Linear Models. 2nd edn. London: Chapman and Hall, 1989
- Lewis CC, Fiscella RG, Kosty T. Need for greater scrutiny of days supply values in DACON calculations. J Manag Care Pharm 2004;10:172-3
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97